BIAF bioAffinity Technologies, Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1712762 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.5%
TTM net income YoY-4.6%
TTM EPS YoY182.9%
Revenue 3-yr CAGR37.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-246.1%
Net margin-278.9%
FCF margin-235.9%
EBITDA margin-239.5%
Returns
ROE-240.5%
ROA-161.4%
ROIC (approx.)-827.2%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets48.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-270.95x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.16M | $9.36M |
| R&D expense | $1.38M | $1.46M |
| SG&A expense | $9.91M | $9.94M |
| Operating income | -$10.57M | -$8.95M |
| Interest expense | $44,372 | $92,475 |
| Pretax income | -$14.87M | -$9.03M |
| Income tax | $44,042 | $11,650 |
| Net income | -$14.91M | -$9.04M |
| EBITDA | -$10.07M | -$8.35M |
| EPS (basic) | -8.66 | -22.50 |
| EPS (diluted) | -8.66 | -22.50 |
| Weighted avg. shares (diluted) | 1.72M | 404,167 |
| Balance sheet | ||
| Cash & equivalents | $6.45M | $1.11M |
| Inventory | $53,548 | $27,608 |
| Current assets | $7.57M | $2.70M |
| PP&E, net | $265,593 | $375,385 |
| Goodwill | $1.40M | $1.40M |
| Intangibles | $716,806 | $775,139 |
| Total assets | $10.96M | $6.51M |
| Current liabilities | $2.91M | $3.10M |
| Total liabilities | $3.68M | $3.91M |
| Shareholders' equity | $7.28M | $2.60M |
| Shares outstanding | 299,826 | 519,158 |
| Cash flow statement | ||
| Operating cash flow | -$9.33M | -$7.26M |
| Capital expenditure | $60,568 | $79,083 |
| Free cash flow | -$9.39M | -$7.34M |
| Investing cash flow | -$60,568 | -$79,083 |
| Financing cash flow | $14.73M | $5.63M |
| Depreciation & amortization | $504,836 | $605,637 |
| Stock-based compensation | $671,474 | $989,681 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.